Rina-S Dual PFS-OS Win Broadens PROC but Numbers and Price Will Decide

Genmab's Rina-S Achieves Significant PFS and OS in Platinum-Resistant Ovarian Cancer

Genmab A/S announced positive topline results from the global Phase 3 RAINFOL™-02 trial of rinatabart sesutecan (Rina-S®) in patients with platinum-resistant ovarian cancer (PROC). The trial met its primary endpoint of progression-free survival (PFS) and its key secondary endpoint of overall survival (OS), demonstrating statistically significant and clinically meaningful improvements compared to investigator’s choice chemotherapy. These benefits were observed across both the intent-to-treat (ITT) and primary analysis set (PAS) populations, regardless of FRα expression or prior mirvetuximab treatment. The safety profile was consistent with previous observations, with no new concerns identified.

• In the intent-to-treat (ITT) population (N=584), Rina-S significantly reduced the risk of disease progression or death by 71% (HR 0.29; 95% CI, 0.23-0.37; p<0.0001). In the primary analysis set (PAS) population (N=492), the drug showed a 67% reduction in risk (HR 0.33; 95% CI, 0.26–0.42; p<0.0001), successfully meeting the primary endpoint of progression-free survival.
• Rina-S also achieved its key secondary endpoint of overall survival (OS), demonstrating a statistically significant and clinically meaningful improvement. In the ITT population, the risk of death was reduced by 57% (HR 0.43; 95% CI, 0.31–0.59; p<0.0001), and in the PAS population, a similar reduction was observed (HR 0.44; 95% CI, 0.31–0.63; p<0.0001).
• The RAINFOL-02 trial evaluated Rina-S against investigator’s choice chemotherapy (paclitaxel, topotecan, PLD, or gemcitabine) in patients with platinum-resistant ovarian cancer, irrespective of FRα expression level or prior mirvetuximab treatment. The observed safety profile of Rina-S was consistent with its known profile, with no new safety signals or unexpected concerns identified during the study.

Addressing the Urgent Unmet Need in Platinum-Resistant Ovarian Cancer

Platinum-resistant ovarian cancer (PROC) remains a major clinical challenge due to limited therapeutic options and poor prognosis. Conventional treatments provide only modest benefits, and the scarcity of effective later-line options has fueled rapid advances in antibody-drug conjugate (ADC) research.

• Limited efficacy of standard single-agent chemotherapy: In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard, with historical single-agent chemotherapy showing ORR 10-20% and PFS 3-4 months. PROC is broadly defined as disease recurrence within 6 months of completing platinum-based chemotherapy and is generally associated with poor outcomes and low response rates to standard chemotherapy.

• Tumor heterogeneity and emergence of resistance mechanisms: Clinical translation remains challenged by response heterogeneity attributable to tumor heterogeneity and the emergence of resistance mechanisms. Mechanisms of platinum resistance are related mostly to the limitation of platinum-DNA adduct formation by changing cellular pharmacology, and to the prevention of cell death after DNA damage due to alterations in DNA repair pathways and cell cycle regulation.

• Immunosuppressive microenvironment and limited immunotherapy activity: Immune checkpoint inhibitors as monotherapy demonstrate low response rates, with activity in ovarian cancer limited by tumor heterogeneity, an immunosuppressive tumor microenvironment, and the lack of robust predictive biomarkers.

• Treatment toxicity and class-specific safety signals: Class-specific adverse events including ocular toxicity, interstitial lung disease (ILD), hepatotoxicity, and peripheral neuropathy challenge clinical translation, GI perforation occurred in 2.2% of bevacizumab-treated patients, and toxicity might be a limiting factor for administration.

RAINFOL-02: Design, Endpoints, and Clinically Meaningful Outcomes

Key trials in platinum-resistant ovarian cancer include randomized phase III comparisons of novel agents versus single-agent chemotherapy, single-arm biomarker-selected studies, and early-phase combination cohorts. Designs differ in folate receptor alpha thresholds, prior lines allowed, and primary endpoints spanning progression-free survival, objective response rate, and overall survival.

Rina-S's Expanding Pipeline and Strategic Position in Oncology

The knowledge base does not have sufficient information to answer this question.

Rina-S®: Reshaping Platinum-Resistant Ovarian Cancer Treatment Beyond FRα

The announcement of positive topline Phase 3 results for rinatabart sesutecan (Rina-S®) marks a pivotal moment for patients battling platinum-resistant ovarian cancer (PROC). This challenging indication has long been characterized by limited treatment options and poor prognoses, with standard chemotherapies often yielding modest progression-free survival rates, typically ranging from 3.7 to 5.4 months. The statistically significant and clinically meaningful improvements in both progression-free survival and overall survival demonstrated by Rina-S® suggest a potential paradigm shift, offering a new hope for extending the lives of these patients.

A particularly compelling aspect of these results is the observed efficacy regardless of folate receptor alpha (FRα) expression or prior mirvetuximab treatment. This distinguishes Rina-S® from existing FRα-targeted antibody-drug conjugates, such as mirvetuximab soravtansine, which require biomarker-driven patient selection. By being FRα-agnostic, Rina-S® could simplify treatment decisions and broaden the eligible patient population, including those with low FRα expression or those who have progressed on prior FRα-targeted therapies. This positions Rina-S® as a strong competitive force, potentially capturing a significant market share beyond biomarker-selected subgroups.

However, several factors warrant careful consideration as Genmab moves forward. The full competitive landscape will become clearer once detailed efficacy data, including specific hazard ratios and absolute survival benefits, are publicly available. Understanding the precise magnitude of benefit relative to current options, such as mirvetuximab (which has shown PFS of 5.6-6.9 months and OS of 12.75-16.46 months in FRα-high patients) or PARP inhibitors in BRCAm patients (PFS 8.2 months, OS 14.9 months), is crucial. While the safety profile was reported as consistent, the detailed incidence and management of adverse events will be critical for clinical adoption. Furthermore, successful market penetration will hinge on strategic pricing, favorable reimbursement policies, and effective integration into evolving treatment guidelines, especially as the ADC space in ovarian cancer continues to grow. The ability of Rina-S® to offer a durable, biomarker-independent benefit could solidify its role as a foundational therapy in the increasingly complex management of PROC.